1. Home
  2. OPRX vs ARMP Comparison

OPRX vs ARMP Comparison

Compare OPRX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

N/A

Current Price

$8.37

Market Cap

137.3M

ML Signal

N/A

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

N/A

Current Price

$3.34

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRX
ARMP
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.3M
199.7M
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
OPRX
ARMP
Price
$8.37
$3.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$12.60
★ $17.50
AVG Volume (30 Days)
128.5K
★ 257.6K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 124.55
N/A
EPS
★ N/A
N/A
Revenue
★ $109,429,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.43
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.78
N/A
52 Week Low
$4.54
$3.08
52 Week High
$22.25
$14.98

Technical Indicators

Market Signals
Indicator
OPRX
ARMP
Relative Strength Index (RSI) 64.98 35.95
Support Level $7.04 N/A
Resistance Level $9.08 $5.63
Average True Range (ATR) 0.38 0.49
MACD 0.08 -0.08
Stochastic Oscillator 95.89 5.26

Price Performance

Historical Comparison
OPRX
ARMP

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: